Valuation: Entrada Therapeutics, Inc.

Market Cap 183M 166M 153M 138M 261M 17.05B 271M 1.84B 730M 9.2B 685M 670M 29.08B P/E 2026 *
-1.25x
P/E 2027 * -1.35x
Enterprise Value 183M 166M 153M 138M 261M 17.05B 271M 1.84B 730M 9.2B 685M 670M 29.08B EV / Sales 2026 *
45.1x
EV / Sales 2027 * 8.97x
Free-Float
84.29%
Yield 2026 *
-
Yield 2027 * -
1 day+4.90%
1 week+1.43%
Current month+17.42%
1 month+10.48%
3 months-27.25%
6 months-9.59%
Current year-48.20%
1 week 4.84
Extreme 4.84
5.49
1 month 4.26
Extreme 4.255
5.49
Current year 4.11
Extreme 4.1092
16.45
1 year 4.11
Extreme 4.1092
16.45
3 years 4.11
Extreme 4.1092
21.79
5 years 4.11
Extreme 4.1092
36.85
10 years 4.11
Extreme 4.1092
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 45 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
3/9/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
Change 5-day change 1-year change 3-year change Capi.($)
+4.90%+1.43%-37.13%-67.17% 183M
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%-1.13%+7.82%+88.90% 60.41B
-1.07%+0.30%+22.91%+86.76% 55.76B
-0.41%-3.31%+8.85%+119.37% 46.98B
-2.20%-5.35%+20.50%+27.16% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.06%-15.09%+137.08%+668.50% 36.09B
-0.77%-2.21%+77.27%+57.96% 32.9B
-1.17%+2.03%-38.24%+391.18% 26.96B
Average -0.48%-0.87%+26.68%+148.89% 41B
Weighted average by Cap. -1.00%-1.48%+33.44%+147.80%

Financials

2026 *2027 *
Net sales 4.05M 3.67M 3.39M 3.06M 5.78M 378M 6M 40.9M 16.18M 204M 15.19M 14.87M 645M 20.36M 18.48M 17.07M 15.4M 29.07M 1.9B 30.19M 206M 81.35M 1.03B 76.37M 74.76M 3.24B
Net income -168M -153M -141M -127M -241M -15.74B -250M -1.7B -673M -8.49B -632M -619M -26.83B -180M -163M -151M -136M -257M -16.78B -266M -1.82B -718M -9.06B -674M -660M -28.61B
Net Debt - -
Projected Income Statement - Annual - Entrada Therapeutics, Inc.
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
18/11/26 USD 5.325 +6.50% 136,862
16/11/26 USD 5.000 -1.77% 607,027
13/11/26 USD 5.090 -1.55% 791,644
12/11/26 USD 5.170 -4.96% 808,660
11/11/26 USD 5.440 +3.62% 760,792
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Entrada Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.000USD
Average target price
18.75USD
Spread / Average Target
+275.00%
  1. Stock Market
  2. Stocks
  3. TRDA Stock